Elevance Health Inc

Elevance Health Inc(ELV)財務資料

$439.950

-5.279 (-1.20%)收盤時

ELV 營收結構

Elevance Health Inc (ELV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Premiums, accounting for 81.8% of total sales, equivalent to $41.02B. Other significant revenue streams include Product revenue and Service fees. Understanding this composition is critical for investors evaluating how ELV navigates market cycles within the Managed Healthcare industry.

ELV 獲利能力與利潤率

Evaluating the bottom line, Elevance Health Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.18%, while the net margin is 2.61%. These profitability ratios, combined with a Return on Equity (ROE) of 11.60%, provide a clear picture of how effectively ELV converts its operational activities into shareholder value.

ELV 同業比較

In the context of the broader market, ELV competes directly with industry leaders such as CI and HUM. With a market capitalization of $93.30B, it holds a leading position in the sector. When comparing efficiency, ELV's gross margin of N/A stands against CI's 8.58% and HUM's N/A. Such benchmarking helps identify whether Elevance Health Inc is trading at a premium or discount relative to its financial performance.

Elevance Health Inc 財務表現

Elevance Health has shown consistent revenue growth, with total revenue increasing from $45.44 billion in Q4 2024 to $51.43 billion in Q3 2026. Net income has also been strong, with Q3 2026 net income reported at $1.36 billion, showcasing the company's profitability.

Financials

FY2026Q3
YoY:
+1.42%
51.43B
Total Revenue
FY2026Q3
YoY:
+22.48%
2.15B
Operating Profit
FY2026Q3
YoY:
+13.14%
1.34B
Net Income after Tax
FY2026Q3
YoY:
+17.86%
6.27
EPS - Diluted
FY2026Q3
YoY:
+29.03%
1000.00M
Free Cash Flow
FY2026Q3
YoY:
+67.36%
3.23
FCF Margin - %
FY2026Q3
YoY:
+11.54%
2.61
Net Margin - %
FY2026Q3
YoY:
-7.13%
8.33
ROIC

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易